ArticleJournal of molecular histology2025
The oncogenic role of TRIM56 in pancreatic cancer via the TRAF6/NF-kB axis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic adenocarcinoma remains one of the most challenging malignancies in oncology, characterized by its exceptionally high mortality rate. TRIM56 (Tripartite Motif Containing 56) has demonstrated significant roles in various cancer types, yet its biological functions in pancreatic cancer remain largely unexplored. This study investigates the expression patterns and functional significance of TRIM56 in pancreatic tumor development and progression. Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan-Meier (K-M) plotter analyses were conducted on The Cancer Genome Atlas-Pancreatic Adenocarcinoma (TCGA-PRAD) datasets. We measured TRIM56 levels in pancreatic tumor samples and cell cultures through quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blotting. Cell Counting Kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EDU), and Transwell assays were employed to evaluate how TRIM56 knockdown affected cellular proliferation, migration, and invasion capabilities. Overexpression in normal pancreatic duct epithelial (HPDE) cells was also performed to assess oncogenic potential of TRIM56. Animal studies utilized both subcutaneous xenograft and liver metastasis models in nude mice to evaluate the impacts of TRIM56 knockdown on tumor growth and metastatic potential. Pancreatic cancer tissues and cell lines exhibited significantly elevated TRIM56 expression. Higher TRIM56 expression was linked to shorter survival times in patients with pancreatic cancer. Reducing TRIM56 expression in BxPC-3 and PANC-1 cells significantly inhibited proliferation, migration, and invasion. At the molecular level, TRIM56 silencing decreased the expression of Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) and inhibited the activation of Nuclear Factor kappa B (NF-κB), suggesting their role in TRIM56's cancer-promoting effects. Overexpression of TRIM56 in normal pancreatic epithelial cells promoted cellular aggressiveness. In xenograft models, TRIM56 knockdown resulted in reduced tumor volume and diminished liver metastases. TRIM56 promotes pancreatic cancer progression through activation of the TRAF6/NF-κB signaling pathway. Targeting TRIM56 represents a promising therapeutic strategy for pancreatic cancer treatment.
Indexed as
Identifiers
40542888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.